Stemline Therapeutics (STML) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Stemline Therapeutics (STML) PT Trimmed at Wedbush; Shares Remain Undervalued
March 17, 2015 12:23 PM EDTWedbush analyst David Nierengarten reiterated an Outperform rating on Stemline Therapeutics (NASDAQ: STML) but trimmed his price target to $35.00 (from $49.00) after the company reported a smaller-than-expected Q4 loss. The target cut comes as they push out their launch timeline. However, they still view the stock... More
